keyword
MENU ▼
Read by QxMD icon Read
search

whole brain radiotherapy

keyword
https://www.readbyqxmd.com/read/28219911/triple-negative-breast-cancer-with-brain-metastasis-in-a-pregnant-woman
#1
Francisco Trinca, Mariana Inácio, Teresa Timóteo, Rui Dinis
A woman aged 35 years was diagnosed with triple-negative breast cancer in October 2012. During the investigation, it was discovered that she was pregnant, the patient decided to have an abortion. She was submitted to a radical modified mastectomy and adjuvant chemotherapy followed by adjuvant breast radiotherapy of the left breast. 2 months after the adjuvant treatment, she began to have headaches and dizziness. The cranial MRI (head MRI) showed brain metastasis. She was then treated with whole brain radiotherapy, stereotactic radiosurgery and concomitant temozolomide which resulted in complete response...
February 20, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28211579/impact-of-treatment-variability-on-survival-in-immuno-competent-and-immuno-compromised-patients-with-primary-central-nervous-lymphoma
#2
Reem Karmali, Chadi Nabhan, Adam M Petrich, Jeffrey Raizer, David Peace, Rimas Lukas, Leo I Gordon, Sanjib Basu, Vineela Chukkapalli, Parameswaran Venugopal
Patients with primary central nervous system lymphoma (PCNSL) treated in the 'real-world' setting do not represent those treated on clinical trials and might not be treated similarly. We studied characteristics and variability in care for 113 newly diagnosed PCNSL patients treated at 5 institutions in the Chicago area between 2000 and 2012. In 111 patients, single modality therapy with a high dose methotrexate (HD-MTX) regimen +/- rituximab, was most commonly employed (n = 65), and 34 underwent radiotherapy (+/- systemic therapy)...
February 17, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28192598/overall-survival-and-the-response-to-radiotherapy-among-molecular-subtypes-of-breast-cancer-brain-metastases-treated-with-targeted-therapies
#3
Jacob A Miller, Rupesh Kotecha, Manmeet S Ahluwalia, Alireza M Mohammadi, Samuel T Chao, Gene H Barnett, Erin S Murphy, Michael A Vogelbaum, Lilyana Angelov, David M Peereboom, John H Suh
BACKGROUND: The current study was conducted to investigate survival and the response to radiotherapy among patients with molecular subtypes of breast cancer brain metastases treated with or without targeted therapies. METHODS: Patients diagnosed with breast cancer brain metastases at a single tertiary care institution were included. The primary outcome was overall survival, whereas secondary outcomes included the cumulative incidences of distant intracranial failure, local failure, and radiation necrosis...
February 13, 2017: Cancer
https://www.readbyqxmd.com/read/28191808/chemoradiation-for-organ-preservation-in-the-treatment-of-muscle-invasive-bladder-cancer-our-institutional-experience
#4
Sweety Gupta, Sudarsan De, Nitin Leekha, Shailesh Chand Sahay, Prekshi Chaudary, Shashank Srinivasan, Malay Nandy
AIM: To assess outcome of chemoradiotherapy for organ preservation in muscle invasive bladder cancer. MATERIAL AND METHODS: 41 patients treated between January 2010 to January 2015 were evaluated in the present study. All patients T staged ranging from cT2-T4a and had undergone maximal transurethral resection of bladder tumour (TURBT). After maximum bladder tumour resection patients were treated with Radiotherapy with or without concurrent chemotherapy. 8 weeks after completion of treatment response was assessed by check cystoscopy, urine cytology and CECT scan Abdomen...
September 2016: Gulf Journal of Oncology
https://www.readbyqxmd.com/read/28179345/correlation-of-tumor-and-peritumoral-edema-volumes-with-survival-in-patients-with-cerebral-metastases
#5
Johannes Kerschbaumer, Marlies Bauer, Marina Popovscaia, Astrid E Grams, Claudius Thomé, Christian F Freyschlag
BACKGROUND: Surgical resection in combination with radiotherapy in selected cases remains the best option for patients with cerebral metastases. Postoperative relapse of brain metastases occurs frequently and can be reduced by postoperative whole-brain radiotherapy (WBRT). Continuous spread of tumor cells from the primary lesions is debated as a cause of recurrence. It is well known that in gliomas, infiltration takes place within the surrounding edema. Obviously, most brain metastases are usually associated with peritumoral edema, which may act as an indicator of infiltration and more aggressive tumor biology...
2017: Anticancer Research
https://www.readbyqxmd.com/read/28178376/treatment-trends-for-patients-with-brain-metastases-does-practice-reflect-the-data
#6
Kiri A Sandler, Narek Shaverdian, Ryan R Cook, Amar U Kishan, Christopher R King, Isaac Yang, Michael L Steinberg, Percy Lee
BACKGROUND: Published guidelines regarding the optimal treatment strategies for brain metastases focus on patients with ≤3 lesions. As delivery techniques for stereotactic radiosurgery (SRS) improve, radiation oncologists are increasingly using it for patients with >3 metastases. In the current study, the authors sought to characterize practice patterns among practitioners to identify areas of controversy. METHODS: A survey of practicing radiation oncologists was distributed via e-mail...
February 8, 2017: Cancer
https://www.readbyqxmd.com/read/28178168/rapid-intracranial-response-to-osimertinib-without-radiotherapy-in-nonsmall-cell-lung-cancer-patients-harboring-the-egfr-t790m-mutation-two-case-reports
#7
Taro Koba, Takashi Kijima, Takayuki Takimoto, Haruhiko Hirata, Yujiro Naito, Masanari Hamaguchi, Tomoyuki Otsuka, Muneyoshi Kuroyama, Izumi Nagatomo, Yoshito Takeda, Hiroshi Kida, Atsushi Kumanogoh
RATIONALE: Most of nonsmall cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) activating mutations eventually acquire resistance to the first EGFR-tyrosine kinase inhibitors (TKIs) therapy after varying periods of treatment. Of note, approximately one-third of those patients develop brain metastases, which deteriorate their quality of life and survival. The effect of systemic chemotherapy on brain metastases after acquisition of EGFR-TKI resistance is limited, and thus far, whole-brain radiation therapy, which may cause the harmful effect on neurocognitive functions, has been the only established therapeutic option for especially symptomatic brain metastases...
February 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28168125/role-of-gamma-knife%C3%A2-radiosurgery-for-the-treatment-of-brain-metastases-from-gynecological-cancers
#8
Andrew Keller, Rahim Ismail, Peter S Potrebko, Julie Pepe, Meiling Wu, Kunal Saigal, Matthew Biagioli, Ravi Shridhar, Robert Holloway, Melvin Field, Nikhil G Rao
OBJECTIVE: Gamma Knife(®) (GK) (Elekta Instruments, Stockholm, Sweden) radiosurgery is well established for treatment of brain metastases. There are limited data on patients treated with GK from gynecological cancers. The authors sought to determine the effectiveness of the GK in patients with brain metastases from gynecological cancers. METHODS: An IRB-approved database was queried for patients with gynecologic cancers treated with GK between June 1996 and May 2016...
December 31, 2016: Curēus
https://www.readbyqxmd.com/read/28167569/use-of-systemic-therapy-concurrent-with-cranial-radiotherapy-for-cerebral-metastases-of-solid-tumors
#9
Maikel Verduin, Jaap D Zindler, Hanneke M A Martinussen, Rob L H Jansen, Sander Croes, Lizza E L Hendriks, Danielle B P Eekers, Ann Hoeben
: The incidence of brain metastases of solid tumors is increasing. Local treatment of brain metastases is generally straightforward: cranial radiotherapy (e.g., whole-brain radiotherapy or stereotactic radiosurgery) or resection when feasible. However, treatment becomes more complex when brain metastases occur while other metastases, outside of the central nervous system, are being controlled with systemic therapy (chemotherapeutics, molecular targeted agents, or monoclonal antibodies)...
February 6, 2017: Oncologist
https://www.readbyqxmd.com/read/28166419/protective-and-therapeutic-effects-of-molsidomine-on-radiation-induced-neural-injury-in-rats
#10
M A Durak, H Parlakpinar, A Polat, N Vardi, K Ekici, M Ucar, O Ozhan, A Yildiz, R Pasahan
We investigated the protective and therapeutic effects of molsidomine (MOL) in a rat model of whole brain radiotherapy (RT). Forty female rats were divided into five groups of eight: group 1, control; group 2, 15 Gy single dose RT (RT); group 3, 4 mg/kg MOL treated for 5 days (MOL); group 4, 4 mg/kg MOL for 5 days, 10 days after RT treatment (RT + MOL); group 5, 4 mg/kg MOL treatment for 5 days before RT treatment and for 5 days after RT treatment (MOL + RT). All rats were sacrificed on day 16. Neurodegenerative changes in the brain and tissue levels of oxidants and antioxidants were evaluated...
February 6, 2017: Biotechnic & Histochemistry: Official Publication of the Biological Stain Commission
https://www.readbyqxmd.com/read/28156676/poor-prognostic-indicators-for-patients-treated-with-radiosurgery-for-brain-metastases
#11
Wendy Anderson, Shannon E Fogh, Jean L Nakamura, Philip Theodosopoulos, Michael McDermott, Patricia Penny Sneed, Steve E Braunstein
: 32 Background: Radiosurgery (SRS) is a standard palliative treatment for patients with limited number of brain metastases. Growing evidence supports the use of SRS for more extensive disease. As SRS is increasingly used in advanced cancer, we sought to identify predictors of survival after SRS to help better inform patients about prognosis. METHODS: We reviewed patients treated with SRS for brain metastases at the University of California, San Francisco (UCSF) from Jan 2010-Dec 2013...
October 9, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28156673/palliative-whole-brain-radiotherapy-predictors-of-prescribing-5-versus-10-fractions
#12
Sarah Baker, Kim Paulson, Brock J Debenham, Sunita Ghosh, David L Ma, Fleur Huang, Karen P Chu, Diane Severin, John Amanie, Tirath Nijjar, Samir Patel, Ericka Wiebe, Brita Lavender Danielson, Bronwen LeGuerrier, Alysa M Fairchild
: 219 Background: The optimal dose for palliative whole brain radiotherapy (WBRT) continues to be debated. Common regimens include 20 Gy in five and 30 Gy in 10 fractions. We aimed to identify factors associated with WBRT dose schedules, hypothesizing that clinical prediction of survival (CPS) would influence prescribing practice. METHODS: Demographic and clinicopathologic data were collected for consecutive patients with brain metastases receiving WBRT through a dedicated palliative radiation oncology clinic...
October 9, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28153049/longitudinal-analysis-of-treatment-induced-genomic-alterations-in-gliomas
#13
E Zeynep Erson-Omay, Octavian Henegariu, S Bülent Omay, Akdes Serin Harmancı, Mark W Youngblood, Ketu Mishra-Gorur, Jie Li, Koray Özduman, Geneive Carrión-Grant, Victoria E Clark, Caner Çağlar, Mehmet Bakırcıoğlu, M Necmettin Pamir, Viviane Tabar, Alexander O Vortmeyer, Kaya Bilguvar, Katsuhito Yasuno, Lisa M DeAngelis, Joachim M Baehring, Jennifer Moliterno, Murat Günel
BACKGROUND: Glioblastoma multiforme (GBM) constitutes nearly half of all malignant brain tumors and has a median survival of 15 months. The standard treatment for these lesions includes maximal resection, radiotherapy, and chemotherapy; however, individual tumors display immense variability in their response to these approaches. Genomic techniques such as whole-exome sequencing (WES) provide an opportunity to understand the molecular basis of this variability. METHODS: Here, we report WES-guided treatment of a patient with a primary GBM and two subsequent recurrences, demonstrating the dynamic nature of treatment-induced molecular changes and their implications for clinical decision-making...
February 2, 2017: Genome Medicine
https://www.readbyqxmd.com/read/28149766/unexpected-long-survival-of-brain-oligometastatic-non-small-cell-lung-cancer-nsclc-treated-with-multimodal-treatment-a-single-center-experience-and-review-of-the-literature
#14
Concetta Elisa Onesti, Daniela Iacono, Silvia Angelini, Salvatore Lauro, Marco Mazzotta, Mario Alberto Occhipinti, Raffaele Giusti, Paolo Marchetti
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide. Fifty percent of the cases are metastatic at diagnosis and about 20% develop brain metastasis. The brain involvement represents a negative prognostic factor. However, some patients could benefit from locoregional treatments of metastatic foci and experience an unexpected long survival or healing. In the previous years some classifications were proposed to identify patients' prognostic category, according to stage of the primary tumor, the timing of metastases occurrence (synchronous or metachronous) and the number of metastatic sites...
December 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28149754/non-small-cell-lung-cancer-nsclc-and-central-nervous-system-cns-metastases-role-of-tyrosine-kinase-inhibitors-tkis-and-evidence-in-favor-or-against-their-use-with-concurrent-cranial-radiotherapy
#15
REVIEW
Panagiota Economopoulou, Giannis Mountzios
Central nervous system (CNS) metastases, including brain metastases (BM) and leptomeningeal metastases (LM) represent a frequent complication of non-small cell lung cancer (NSCLC). Patients with BM comprise a heterogeneous group, with a median survival that ranges from 3 to 14 months. However, in the majority of patients, the occurrence of CNS metastases is usually accompanied by severe morbidity and substantial deterioration in quality of life. Local therapies, such as whole brain radiotherapy (WBRT), stereotactic radiosurgery (SRS) or surgical resection, either alone or as part of a multimodality treatment are available treatment strategies for BM and the choice of therapy varies depending on patient group and prognosis...
December 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28139076/gamma-knife-radiosurgery-for-brain-metastases-from-gastrointestinal-primary
#16
Brandi R Page, Edina C Wang, Lance White, Emory McTyre, Ann Peiffer, Angela Alistar, Frank Mu, Amritraj Loganathan, John Daniel Bourland, Adrian W Laxton, Stephen B Tatter, Michael D Chan
INTRODUCTION: In this study, we assessed clinical outcomes of patients with brain metastases from a gastrointestinal (GI) primary cancer and patterns of failure after stereotactic radiosurgery including failure within the radiosurgical volume, distant failure and leptomeningeal failure (LMF). We also assessed other factors associated with the patients' neurologic and extraneuraxial disease that may affect clinical outcomes. METHODS: We reviewed our institutional series of 62 consecutive patients with brain metastases treated with stereotactic radiosurgery, which included 17 patients with oesophageal, 44 patients with colorectal and one patient with anal canal primary...
January 31, 2017: Journal of Medical Imaging and Radiation Oncology
https://www.readbyqxmd.com/read/28126476/optimization-of-brain-metastases-radiotherapy-with-tomohda
#17
Slav Yartsev, Glenn Bauman
An upgrade of the helical tomotherapy technology by introducing variable fan-field width (dynamic jaws) reduced the penumbra in superior-inferior direction for the target. Possible implementation of this upgrade even for the cases of the targets with different dose prescriptions is proposed. An example of brain metastasis in proximity to the optical apparatus in need of the whole brain irradiation of 30 Gy and higher dose to the lesion is considered.
January 23, 2017: Medical Dosimetry: Official Journal of the American Association of Medical Dosimetrists
https://www.readbyqxmd.com/read/28113019/management-of-brain-metastases-in-tyrosine-kinase-inhibitor-na%C3%A3-ve-epidermal-growth-factor-receptor-mutant-non-small-cell-lung-cancer-a-retrospective-multi-institutional-analysis
#18
William J Magnuson, Nataniel H Lester-Coll, Abraham J Wu, T Jonathan Yang, Natalie A Lockney, Naamit K Gerber, Kathryn Beal, Arya Amini, Tejas Patil, Brian D Kavanagh, D Ross Camidge, Steven E Braunstein, Lauren C Boreta, Suresh K Balasubramanian, Manmeet S Ahluwalia, Niteshkumar G Rana, Albert Attia, Scott N Gettinger, Joseph N Contessa, James B Yu, Veronica L Chiang
Purpose Stereotactic radiosurgery (SRS), whole-brain radiotherapy (WBRT), and epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are treatment options for brain metastases in patients with EGFR-mutant non-small-cell lung cancer (NSCLC). This multi-institutional analysis sought to determine the optimal management of patients with EGFR-mutant NSCLC who develop brain metastases and have not received EGFR-TKI. Materials and Methods A total of 351 patients from six institutions with EGFR-mutant NSCLC developed brain metastases and met inclusion criteria for the study...
January 23, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28109544/cost-effectiveness-of-prophylactic-cranial-irradiation-with-hippocampal-avoidance-in-limited-stage-small-cell-lung-cancer
#19
Xuanlu M Qu, Mark V Mishra, Glenn S Bauman, Ben Slotman, Minesh Mehta, Vinai Gondi, Alexander V Louie
BACKGROUND AND PURPOSE: Prophylactic cranial irradiation (PCI) in limited stage small cell lung cancer (LS-SCLC) prevents brain metastases and improves survival, with the potential for neurocognitive toxicity. RTOG0933 demonstrated that hippocampal avoidance (HA) during whole brain radiotherapy preserves neurocognition. This study's objective was to evaluate the cost-effectiveness of HA-PCI in LS-SCLC through decision analysis. MATERIALS AND METHODS: A Markov model was developed to simulate the clinical course of LS-SCLC who received HA-PCI or conventional PCI (C-PCI)...
January 18, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28104300/challenges-and-opportunities-in-primary-cns-lymphoma-a-systematic-review
#20
REVIEW
Mariana N Kerbauy, Fabio Y Moraes, Benjamin H Lok, Jennifer Ma, Lucila N Kerbauy, Daniel E Spratt, Fabio P S Santos, Guilherme F Perini, Alejandro Berlin, Caroline Chung, Nelson Hamerschlak, Joachim Yahalom
BACKGROUND: Historically, high-dose methotrexate (HD-MTX) plus consolidation chemotherapy and/or whole brain radiotherapy (WBRT) has been the gold standard on Primary Central Nervous System Lymphoma (PCNSL) management. We sought to examine and summarize the data, on clinical trial (CT) setting, investigating multi-modality treatment to PCNSL. METHODS: We performed a systematic review of electronic databases (Medline, EMBASE, Cochrane Database and clinicaltrials...
January 16, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
keyword
keyword
100499
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"